Ascend Wellness Holdings, Inc.
AAWHDrugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
ASN-002
Basal Cell Carcinoma
Afimoxifene (0.057%) in hydroalcoholic gel
Cyclic Breast Pain, Cyclic Mastalgia
Dihydrotestosterone (0.7%) in hydroalcoholic gel
Hypogonadism
Dihydrotestosterone (DHT) gel (0.7%)
Healthy
5-FU
Basal Cell Nevus Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ASN-002 | Phase 2 | Basal Cell Carcinoma | - | - |
Afimoxifene (0.057%) in hydroalcoholic gel | Phase 2 | Cyclic Breast Pain, Cyclic Mastalgia | - | - |
Dihydrotestosterone (0.7%) in hydroalcoholic gel | Phase 2 | Hypogonadism | - | - |
Dihydrotestosterone (DHT) gel (0.7%) | Phase 2 | Healthy | - | - |
5-FU | Phase 2 | Basal Cell Nevus Syndrome | - | - |
Frequently asked questions
What is in Ascend Wellness Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Ascend Wellness Holdings, Inc.'s (AAWH) pipeline across Phase 2. Its lead program is ASN-002 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ascend Wellness Holdings, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Ascend Wellness Holdings, Inc. (AAWH) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track AAWH biotech catalysts?→
Add AAWH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ascend Wellness Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.